TRANSGENE:Third Quarter Marked by Progress in Clinical Development and Research

information fournie par Boursorama •19/10/2017 à 18:00

• 2 new clinical trials started during the third quarter
• Launch of the Invir.IOTM platform (next generation of multifunctional oncolytic viruses) and collaboration with Randox
• ?40.0 Million in cash and cash equivalents as of September 30, 2017 and cash burn in line with expectations

Strasbourg, France, October 19, 2017, 6:00 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, today announces its business update for the quarter ending September 30, 2017.

During the quarter, Transgene continued implementing its development plan. Two clinical trials have started, combining Pexa-Vec with nivolumab (liver cancer), and combining TG4001 with avelumab (HPV-positive head and neck cancers). In the United States, the Food and Drug Administration has granted the clearance to launching the trial evaluating TG4010 in lung cancer. To date, seven clinical trials evaluating Transgene immunotherapies are underway. They will enable our 5 products to deliver clinical results by 2018.
In parallel, Transgene has published scientific results in peer-reviewed journals that consolidate the mechanism of action of TG4010.
Finally, with Invir.IOTM, Transgene confirmed its ambition and its pioneering vision in the field of oncolytic viruses. This platform will enable the Company to design a new generation of multifunctional oncolytic viruses. A first research agreement was signed with Randox.
.../...